PURPOSE: To assess the efficacy and @entity137 of combined modality therapy with short intensive primary chemotherapy in the treatment of @entity706 ( @entity706 ). METHODS AND MATERIALS: Prospective study of 31 nonimmunodeficient @entity1 with @entity706 treated with initial chemotherapy (13 shortened MACOP-B; and 18 modified MACOP with high dose @entity1499 ) followed by radiotherapy (whole brain and a boost). @entity1 were aged 18-72 years (median 51 years). Eight @entity1 had positive CSF cytology of which one had @entity693 ; one @entity1 had vitreous involvement. RESULTS: The overall complete response (CR) rate after chemotherapy and radiotherapy was 69% (95% Confidence Interval: 49-84%). At a median follow-up of 24 months (4 months to 10 years) median survival was 23 months and 5-year survival 34%. Age, sex, performance status, number of lesions, CSF cytology, and extent of surgery were not of prognostic significance for survival on univariate analysis. Eleven @entity1 developed @entity33 (Grade 3+) and 21 hematological @entity137 (Grade 3+) with 22 septicemic episodes in 15 @entity1 . Three @entity1 developed @entity303 , one assumed to be treatment related, and two due to recurrent disease. CONCLUSION: The survival results of short intensive primary chemotherapy followed by radiotherapy are similar to the results of chemotherapy in Stage @entity1893 , although the treatment was associated with high morbidity. The apparently favorable results when compared to radiotherapy alone may at least in part be due to selection of @entity1 with good prognostic factors. To confirm the benefit of combined chemotherapy and radiotherapy over either of the two modalities alone requires evaluation in large prospective and ideally randomized studies.

Short intensive primary chemotherapy and radiotherapy in sporadic XXXX ( @entity706 ).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity706 :: ('MESH:D008223', 'Disease') :: ['PCL', 'primary CNS lymphoma'] @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity693 :: ('MESH:D008581', 'Disease') :: ['spinal meningeal disease'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["IV aggressive systemic non-Hodgkin's lymphoma"] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity706 :: (MESH:D008223,Disease) :: ['primary CNS lymphoma']
